Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies.

Jin Tang, Feng Chen, Yifan Wu, Guoqian Hu

Journal: International urology and nephrology 2024;56(12):3807-3813

PMID: 38963512

Abstract

The immune system can lead to a variety of renal diseases through direct or indirect mechanisms. In immune-mediated nephropathy, though standardized treatment, there are still a small number of patients with further decline in renal function, which may even progress to renal failure; sodium-glucose cotransporter protein 2 (SLC5A2,SGLT2) inhibitors not only can significantly reduce blood glucose, but also have an additional protective effect on the kidneys and the heart; this review concludes the potential mechanism of the renal protective effect of SGLT2i and the new advances in the recent years in common immune-mediated nephropathies, which can provide new theoretical references to optimize the therapeutic strategy of common immune-mediated nephropathies.

Address: Department of Urology, Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China.; Department of Nephrology, Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China. [email protected].; Department of Urology, Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China. [email protected].

DOI: 10.1007/s11255-024-04141-2

Link outs

Subscription / membership required

Full Text Sources:

https://doi.org/10.1007/s11255-024-04141-2

MeSH Terms: Sodium-Glucose Transporter 2 Inhibitors, Humans, Kidney Diseases